Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Front Pharmacol. 2022;13:967317 DOI: 10.3389/fphar.2022.967317
Few head-to-head trials have been conducted to compare the efficacy and safety of MRAs in DKD. A systematic review and network meta-analysis of 12 randomised trials revealed that high-dose finerenone, esaxerenone and apararenone were associated with greater reductions in UACR vs baseline than low-dose finerenone. None of the MRAs showed significant changes in eGFR vs baseline. Regarding adverse events, spironolactone, esaxerenone and finerenone 20 mg were associated with a higher risk of hyperkalaemia.